COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

An Open-Label, Phase 1 Study Of KHK2455 In Combination With Avelumab In Adult Subjects With Locally Advanced Or Metastatic Urothelial Carcinoma

Protocol No
KYOWA-2455-002
Principal Investigator
Deepak Kilari
Phase
I
Summary
KHK2455 (the study medication) is an IDO1 inhibitor (a molecule) designed to help prevent tumor growth and to help your body’s immune system react against your cancer. Avelumab is a PD-L1 (type of protein) binding drug that is also made up of a substance that works against cancer and can help your immune system react against cancer.
Description
The main purposes of this study are to:
1. Test and study the side effects (to determine the safety) of KHK2455 when taken in combination with avelumab; and
2. Identify the highest dose of KHK2455 that can be given and safely tolerated in combination with avelumab.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL